Replacing 99mTc with 111In Improves MORF/cMORF Pretargeting by Reducing Intestinal Accumulation

Guozheng Liu; Dengfeng Cheng; Shuping Dou; Xiangji Chen; Minmin Liang; P. Hendrik Pretorius; Mary Rusckowski; Donald J. Hnatowich

doi:10.1007/s11307-009-0209-0

Molecular Imaging and Biology

September 2009, Volume 11, Issue 5, pp 303–307

Replacing ^99mTc with ¹¹¹In Improves MORF/cMORF Pretargeting by Reducing Intestinal Accumulation

Authors
Authors and affiliations

Guozheng LiuEmail author
Dengfeng Cheng
Shuping Dou
Xiangji Chen
Minmin Liang
P. Hendrik Pretorius
Mary Rusckowski
Donald J. Hnatowich

Brief Article

First Online:: 27 March 2009

Received:: 26 November 2008
Accepted:: 18 December 2008

13 Citations
87 Downloads

Abstract

Purpose

To reduce accumulation in the abdomen by MORF/cMORF pretargeting, ¹¹¹In was compared to ^99mTc as the radiolabel.

Procedures

After receiving either ^99mTc (MAG3)-cMORF or ¹¹¹In (DTPA)-cMORF, normal mice were imaged and killed for pharmacokinetics. Thereafter, tumored mice were pretargeted with MORF-antibody, 48 h later were given an injection of ^99mTc- or ¹¹¹In-cMORF, and finally were imaged repeatedly.

Results

The cMORF biodistribution in both normal and pretargeted tumored mice was influenced by its radiolabel. While excretion of both ^99mTc-cMORF and ¹¹¹In-cMORF was rapid and mainly through the kidneys, about 2% of ^99mTc accumulated in the intestines compared to essentially no intestinal accumulation for ¹¹¹In at any time. Tumor accumulation was unchanged.

Conclusion

In applications of MORF/cMORF pretargeting intended to image organs deep within the abdomen such as the pancreas, radiolabeling with ¹¹¹In may be superior to ^99mTc.

Key words

Pretargeting Anticancer Antibodies Tumor Radioimmunotargeting

References

1.
Karacay H, Brard PY, Sharkey RM, Chang CH, Rossi EA, McBride WJ, Ragland DR, Horak ID, Goldenberg DM (2005) Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res 11:7879–7885PubMedCrossRefGoogle Scholar
2.
Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, Hansen HJ, Horak ID, Goldenberg DM (2005) Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 11:1250–1255PubMedCrossRefGoogle Scholar
3.
Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, Theodore LJ, Wilbur DS, Matthews DC, Press OW (2003) Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 101:2340–2348PubMedCrossRefGoogle Scholar
4.
Subbiah K, Hamlin DK, Pagel JM, Wilbur DS, Meyer DL, Axworthy DB, Mallett R, Theodore LJ, Stayton PS, Press OW (2003) Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med 44:437–445PubMedGoogle Scholar
5.
Magnani P, Paganelli G, Modorati G, Zito F, Songini C, Sudati F, Koch P, Maecke HR, Brancato R, Siccardi AG, Fazio F (1996) Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucl Med 37:967–971PubMedGoogle Scholar
6.
Robert AS, Cokkinides V, Harmon JE (2006) American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 56:11–25CrossRefGoogle Scholar
7.
Buchsbaum DJ (1995) Experimental approaches to increase radiolabeled antibody localization in tumors. Cancer Res 55:5729s–5732sPubMedGoogle Scholar
8.
Hiltunen JV (1993) Search for new and improved radiolabeling methods for monoclonal antibodies. A review of different methods. Acta Oncol 32:831–839PubMedCrossRefGoogle Scholar
9.
Quadri SM, Vriesendorp HM (1998) Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates. Q J Nucl Med 42:250–261PubMedGoogle Scholar
10.
Quadri SM, Vriesendorp HM, Leichner PK, Williams JR (1993) Evaluation of indium-111- and yttrium-90-labeled linker-immunoconjugates in nude mice and dogs. J Nucl Med 34:938–945PubMedGoogle Scholar
11.
Liu G, Dou S, Pretorius PH, Liu X, Rusckowski M, Hnatowich DJ (2008) Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF. Eur J Nucl Med Mol Imaging 35:272–280PubMedCrossRefGoogle Scholar
12.
Liu G, Dou S, Mardirossian G, He J, Zhang S, Liu X, Rusckowski M, Hnatowich DJ (2006) Successful radiotherapy of tumor in pretargeted mice by ¹⁸⁸Re radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analog. Clin Can Res 12:4958–1964CrossRefGoogle Scholar
13.
Liu G, Dou S, He J, Yin D, Gupta S, Zhang S, Wang Y, Rusckowski M, Hnatowich DJ (2006) Radiolabeling of MAG₃-morpholino oligomers with ¹⁸⁸Re at high labeling efficiency and specific radioactivity for tumor pretargeting. Appl Radiat Isot 64:971–978PubMedCrossRefGoogle Scholar
14.
Liu G, Dou S, He J, Liu X, Rusckowski M, Hnatowich DJ (2007) Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice. Eur J Nucl Med Mol Imaging 34:237–246PubMedCrossRefGoogle Scholar
15.
Duncan JR, Behr TM, DeNardo SJ (1997) Intracellular fate of radiometals. J Nucl Med 38:829PubMedGoogle Scholar
16.
Duncan JR, Stephenson MT, Wu HP, Anderson CJ (1997) Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, hepatocyte lysosomes. Cancer Res 57:659–671PubMedGoogle Scholar

Copyright information

Authors and Affiliations

Guozheng Liu
- 1
Email author
Dengfeng Cheng
- 1
Shuping Dou
- 1
Xiangji Chen
- 1
Minmin Liang
- 1
P. Hendrik Pretorius
- 1
Mary Rusckowski
- 1
Donald J. Hnatowich
- 1

1.Division of Nuclear Medicine, Department of RadiologyUniversity of Massachusetts Medical SchoolWorcesterUSA

About this article

Cite this article as:: Liu, G., Cheng, D., Dou, S. et al. Mol Imaging Biol (2009) 11: 303. doi:10.1007/s11307-009-0209-0